Clinical Trials
2,295 trialsNCT03765983 2026-05-27
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04345913 2026-05-27
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT06461663 2026-05-27
CairnSurgical Breast Cancer Locator (BCL) Post-Market Study
CairnSurgical, Inc.
Phase NA Completed
NCT00310180 2026-05-26
TAILORx
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01272037 2026-05-26
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04699630 2026-05-22
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT04764292 2026-05-22
SCEMAM
University of Pittsburgh
Phase 4 Completed
NCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT02364557 2026-05-19
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
NRG Oncology
Phase 2/3 Completed
NCT03180294 2026-05-19
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NRG Oncology
Phase 2 Completed
NCT00376597 2026-05-18
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT03587740 2026-05-18
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05871125 2026-05-18
Identifying Ideal Reimbursement "Dose" to Reduce Clinical Trial-related Financial Toxicity
University of Alabama at Birmingham
Phase NA Completed
NCT03624478 2026-05-15
Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery
Mayo Clinic
Phase 2 Completed
NCT03983382 2026-05-15
A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT04001829 2026-05-15
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT02297438 2026-05-14
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT05085002 2026-05-14
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
Phase 2 Terminated
NCT00433511 2026-05-12
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00631852 2026-05-12
A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer
Southern Illinois University
Phase 2 Completed
NCT01624220 2026-05-12
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
Phase NA Completed
NCT02445391 2026-05-12
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT02689427 2026-05-12
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02926911 2026-05-12
COMET
Alliance Foundation Trials, LLC.
Phase NA Active not recruiting
NCT03941730 2026-05-12
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04739761 2026-05-12
DESTINY-B12
AstraZeneca
Phase 3 Active not recruiting
NCT04251533 2026-05-11
EPIK-B3
Novartis
Phase 3 Terminated
NCT04505826 2026-05-11
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04175210 2026-05-07
PRART
Weill Medical College of Cornell University
Phase 3 Active not recruiting
NCT02032823 2026-05-06
OlympiA
AstraZeneca
Phase 3 Active not recruiting
NCT04268134 2026-05-06
ALTA
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT04331067 2026-05-06
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT05176860 2026-05-06
Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy
Varian, a Siemens Healthineers Company
Phase NA Completed
NCT01670500 2026-05-05
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT03179904 2026-05-05
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT03794388 2026-05-05
CAPTRANE
Institut Cancerologie de l'Ouest
Phase 3 Completed
NCT05076266 2026-05-05
COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation
Eastern Cooperative Oncology Group
Terminated
NCT05104866 2026-05-05
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
Phase 3 Active not recruiting
NCT01116648 2026-05-04
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03317405 2026-05-04
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02311933 2026-05-01
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02498613 2026-05-01
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04414202 2026-05-01
INTRA-OBS
Institut du Cancer de Montpellier - Val d'Aurelle
Active not recruiting
NCT02115282 2026-04-30
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02700386 2026-04-30
Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes
University of Colorado, Denver
Phase 2 Completed
NCT04305496 2026-04-30
CAPItello-291
AstraZeneca
Phase 3 Active not recruiting
NCT03218826 2026-04-29
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT03633331 2026-04-29
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT03939897 2026-04-29
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting